Changes in Beneficial Ownership · 4
Fennec Pharmaceuticals Inc.
Changes in Beneficial Ownership
Structured filing — 4
form4-06102026_090645.xml
Filing details
- Report period
- 2026-06-10
- Issuer
- FENNEC PHARMACEUTICALS INC.
- Issuer CIK
- 0001211583
- Trading symbol
- FENC
Reporting owner 1
- Name
- RALLIS CHRIS A
- Reporting owner CIK
- 0001185945
- Relationship
- Director
- Address
- C/O FENNEC PHARMACEUTICALS, INC., PO BOX 13628, 68 TW ALEXANDER DRIVE, RESEARCH TRIANGLE PARK, NC, 27709
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option[F1] | 8.70 | 2026-06-10 | A · Form 4 | 20,000 | A | 8.70 | 2026-06-10[F2] | 2036-06-10 | Common shares | 20,000 | 200,000 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
Signature 1
- Signed
- /s/ Chris Rallis
- Date
- 2026-06-10
Company context
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSIÒ.